Product Name | Linezolid |
Appearance | White powder |
Specification | 99% |
Test Method | HPLC |
Storage | Keep in a cool, dry, dark location in a tightly sealed container or cylinder. |
Shelf Time | 24 months |
| MOQ | 1kg |
Unique Antibacterial Mechanism
Linezolid belongs to the oxazolidinone class of antibiotics, and its mechanism of action is very unique and precise:
Target: It acts on the 50S subunit of the bacterial ribosome.
Mechanism of Action: It inhibits the initiation stage of bacterial protein synthesis. As we can imagine, bacteria need to continuously synthesize new proteins to grow and reproduce. Linezolid effectively inhibits bacterial growth by blocking the"starting"step of this synthesis process, preventing the bacterial protein factories (ribosomes) from operating normally.
Significance: Because this mechanism of action is completely different from other common antibiotics (such as β-lactams, macrolides, and glycopeptides), it is less likely to develop cross-resistance with them. This makes it a powerful weapon against drug-resistant bacteria.
Strong Antibacterial Spectrum
Linezolid primarily targets Gram-positive bacteria, and is particularly known for its ability to combat drug-resistant bacteria:
Methicillin-resistant Staphylococcus aureus (MRSA)
Vancomycin-resistant Enterococcus (VRE)
Penicillin-resistant Streptococcus pneumoniae (PRSP)
Clinical Efficacy
In patients, Linezolid's efficacy is demonstrated through:
Bactericidal Action: Against the key pathogens listed above, Linezolid exhibits bactericidal activity (i.e., it kills bacteria, not just inhibits their growth).
Effective Infection Clearance: By inhibiting or killing pathogens, it effectively controls infection, alleviates clinical symptoms (such as fever, cough, pain, etc.) of diseases caused by these bacteria, such as pneumonia, bacteremia, and skin infections, and ultimately cures the infection.
Vancomycin-resistant Enterococcus (VRE) Infections
This is one of the core applications of Linezolid. When the infection is caused by VRE, Linezolid is one of the few remaining effective options, commonly used to treat VRE-related bacteremia, endocarditis, etc.
Hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP)
Especially when pneumonia is suspected or confirmed to be caused by MRSA, Linezolid is considered one of the preferred drugs, and its efficacy is widely recognized.
Complicated Skin and Soft Tissue Infections
Used to treat complicated skin infections caused by MRSA, Streptococcus pyogenes, etc., such as deep abscesses, surgical wound infections, ulcer infections, etc.
Complicated Bacteremia
When infection from any of the above sites enters the bloodstream, causing bacteremia or sepsis, if the pathogen is one of the above-mentioned drug-resistant Gram-positive bacteria, Linezolid is also a key treatment option.
